APO Research
Talk to an analyst

APO RESEARCH · REPORT

Necrotizing Ulcerative Gingivitis (NUG)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Necrotizing Ulcerative Gingivitis (NUG) Market Analysis and Forecast 2026-2032

30 December 2025196 pages

Choose your research edition.

Industry ResearchNecrotizing Ulcerative Gingivitis (NUG) Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Necrotizing Ulcerative Gingivitis (NUG) Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Necrotizing Ulcerative Gingivitis (NUG) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Necrotizing Ulcerative Gingivitis (NUG) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Necrotizing Ulcerative Gingivitis (NUG) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Necrotizing Ulcerative Gingivitis (NUG) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Necrotizing Ulcerative Gingivitis (NUG) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Necrotizing Ulcerative Gingivitis (NUG) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Necrotizing Ulcerative Gingivitis (NUG) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Necrotizing Ulcerative Gingivitis (NUG) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Necrotizing Ulcerative Gingivitis (NUG) include Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics, Otsuka Pharmaceutical, GlaxoSmithKline, Mylan, Merck, Novartis and Sanofi, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Necrotizing Ulcerative Gingivitis (NUG), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Necrotizing Ulcerative Gingivitis (NUG), also provides the revenue of main regions and countries. Of the upcoming market potential for Necrotizing Ulcerative Gingivitis (NUG), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Necrotizing Ulcerative Gingivitis (NUG) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Necrotizing Ulcerative Gingivitis (NUG) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Necrotizing Ulcerative Gingivitis (NUG) revenue, projected growth trends, production technology, application and end-user industry.

Necrotizing Ulcerative Gingivitis (NUG) Segment by Company

Abbott Laboratories

Eli Lilly and Company

Hindustan Antibiotics

Otsuka Pharmaceutical

GlaxoSmithKline

Mylan

Merck

Novartis

Sanofi

Teva Pharmaceutical

Necrotizing Ulcerative Gingivitis (NUG) Segment by Type

Medication

Surgery

Necrotizing Ulcerative Gingivitis (NUG) Segment by Application

Homecare

Pharmacies

Hospitals

Others

Necrotizing Ulcerative Gingivitis (NUG) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Necrotizing Ulcerative Gingivitis (NUG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Necrotizing Ulcerative Gingivitis (NUG) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Necrotizing Ulcerative Gingivitis (NUG).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Necrotizing Ulcerative Gingivitis (NUG) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Necrotizing Ulcerative Gingivitis (NUG) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Necrotizing Ulcerative Gingivitis (NUG) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Medication Major Player Table 3. Surgery Major Player Table 4. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Homecare Major Player Table 6. Pharmacies Major Player Table 7. Hospitals Major Player Table 8. Others Major Player Table 9. Necrotizing Ulcerative Gingivitis (NUG) Industry Trends Table 10. Necrotizing Ulcerative Gingivitis (NUG) Industry Drivers Table 11. Necrotizing Ulcerative Gingivitis (NUG) Industry Opportunities and Challenges Table 12. Necrotizing Ulcerative Gingivitis (NUG) Industry Restraints Table 13. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Necrotizing Ulcerative Gingivitis (NUG) Market Share by Region (2021-2026) Table 16. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Necrotizing Ulcerative Gingivitis (NUG) Market Share by Region (2027-2032) Table 18. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Players (2021-2026) Table 20. Global Necrotizing Ulcerative Gingivitis (NUG) Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Necrotizing Ulcerative Gingivitis (NUG) Key Players Headquarters & Area Served Table 22. Global Necrotizing Ulcerative Gingivitis (NUG) Players, Product Type & Application Table 23. Global Necrotizing Ulcerative Gingivitis (NUG) Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Necrotizing Ulcerative Gingivitis (NUG) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Type (2021-2026) Table 30. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Type (2027-2032) Table 31. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Application (2021-2026) Table 35. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Application (2027-2032) Table 36. Abbott Laboratories Company Information Table 37. Abbott Laboratories Business Overview Table 38. Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 40. Abbott Laboratories Recent Development Table 41. Eli Lilly and Company Company Information Table 42. Eli Lilly and Company Business Overview Table 43. Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 45. Eli Lilly and Company Recent Development Table 46. Hindustan Antibiotics Company Information Table 47. Hindustan Antibiotics Business Overview Table 48. Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 50. Hindustan Antibiotics Recent Development Table 51. Otsuka Pharmaceutical Company Information Table 52. Otsuka Pharmaceutical Business Overview Table 53. Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 55. Otsuka Pharmaceutical Recent Development Table 56. GlaxoSmithKline Company Information Table 57. GlaxoSmithKline Business Overview Table 58. GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 60. GlaxoSmithKline Recent Development Table 61. Mylan Company Information Table 62. Mylan Business Overview Table 63. Mylan Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Mylan Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 65. Mylan Recent Development Table 66. Merck Company Information Table 67. Merck Business Overview Table 68. Merck Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Merck Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 70. Merck Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Novartis Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 75. Novartis Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Sanofi Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 80. Sanofi Recent Development Table 81. Teva Pharmaceutical Company Information Table 82. Teva Pharmaceutical Business Overview Table 83. Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio Table 85. Teva Pharmaceutical Recent Development Table 86. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026) & (US$ Million) Table 87. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032) & (US$ Million) Table 88. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026) & (US$ Million) Table 89. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032) & (US$ Million) Table 90. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021-2026) & (US$ Million) Table 92. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (US$ Million) & (2027-2032) Table 93. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021-2026) & (US$ Million) Table 99. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (US$ Million) & (2027-2032) Table 100. China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026) & (US$ Million) Table 101. China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032) & (US$ Million) Table 102. China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026) & (US$ Million) Table 103. China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026) & (US$ Million) Table 105. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032) & (US$ Million) Table 106. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026) & (US$ Million) Table 107. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Region (US$ Million) & (2021-2026) Table 110. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Region (US$ Million) & (2027-2032) Table 111. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026) & (US$ Million) Table 112. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032) & (US$ Million) Table 113. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026) & (US$ Million) Table 114. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032) & (US$ Million) Table 115. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021-2026) & (US$ Million) Table 117. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (US$ Million) & (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Necrotizing Ulcerative Gingivitis (NUG) Image Figure 2. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Medication Image Figure 5. Surgery Image Figure 6. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Homecare Image Figure 9. Pharmacies Image Figure 10. Hospitals Image Figure 11. Others Image Figure 12. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size (US$ Million) & (2021-2032) Figure 13. Global Necrotizing Ulcerative Gingivitis (NUG) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Necrotizing Ulcerative Gingivitis (NUG) Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Necrotizing Ulcerative Gingivitis (NUG) Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Type (2021-2032) Figure 20. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Application (2021-2032) Figure 23. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032) Figure 25. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032) Figure 26. North America Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Country (2021-2032) Figure 27. United States Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032) Figure 32. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032) Figure 33. Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Country (2021-2032) Figure 34. Germany Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032) Figure 44. China Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032) Figure 45. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032) Figure 47. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032) Figure 48. Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Region (2021-2032) Figure 49. Japan Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032) Figure 57. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032) Figure 58. SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Country (2021-2032) Figure 59. Brazil Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Necrotizing Ulcerative Gingivitis (NUG) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Medication
  • Surgery
Applications
  • Homecare
  • Pharmacies
  • Hospitals
  • Others
Companies covered
  • Abbott Laboratories
  • Eli Lilly and Company
  • Hindustan Antibiotics
  • Otsuka Pharmaceutical
  • GlaxoSmithKline
  • Mylan
  • Merck
  • Novartis
  • Sanofi
  • Teva Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Necrotizing Ulcerative Gingivitis (NUG) Market by Type
  3. 1.2.1 Global Necrotizing Ulcerative Gingivitis (NUG) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Medication
  5. 1.2.3 Surgery
  6. 1.3 Necrotizing Ulcerative Gingivitis (NUG) Market by Application
  7. 1.3.1 Global Necrotizing Ulcerative Gingivitis (NUG) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Homecare
  9. 1.3.3 Pharmacies
  10. 1.3.4 Hospitals
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Necrotizing Ulcerative Gingivitis (NUG) Market Dynamics
  1. 2.1 Necrotizing Ulcerative Gingivitis (NUG) Industry Trends
  2. 2.2 Necrotizing Ulcerative Gingivitis (NUG) Industry Drivers
  3. 2.3 Necrotizing Ulcerative Gingivitis (NUG) Industry Opportunities and Challenges
  4. 2.4 Necrotizing Ulcerative Gingivitis (NUG) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Necrotizing Ulcerative Gingivitis (NUG) Market Perspective (2021-2032)
  2. 3.2 Global Necrotizing Ulcerative Gingivitis (NUG) Growth Trends by Region
  3. 3.2.1 Global Necrotizing Ulcerative Gingivitis (NUG) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Necrotizing Ulcerative Gingivitis (NUG) Market Size by Region (2021-2026)
  5. 3.2.3 Global Necrotizing Ulcerative Gingivitis (NUG) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Players
  2. 4.1.1 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Players (2021-2026)
  3. 4.1.2 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Necrotizing Ulcerative Gingivitis (NUG) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Necrotizing Ulcerative Gingivitis (NUG) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Necrotizing Ulcerative Gingivitis (NUG) Key Players Headquarters & Area Served
  7. 4.4 Global Necrotizing Ulcerative Gingivitis (NUG) Players, Product Type & Application
  8. 4.5 Global Necrotizing Ulcerative Gingivitis (NUG) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Necrotizing Ulcerative Gingivitis (NUG) Market CR5 and HHI
  11. 4.6.3 2025 Necrotizing Ulcerative Gingivitis (NUG) Tier 1, Tier 2, and Tier 3
5 Necrotizing Ulcerative Gingivitis (NUG) Market Size by Type
  1. 5.1 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2032)
  3. 5.3 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Type (2021-2032)
6 Necrotizing Ulcerative Gingivitis (NUG) Market Size by Application
  1. 6.1 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2032)
  3. 6.3 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott Laboratories
  2. 7.1.1 Abbott Laboratories Company Information
  3. 7.1.2 Abbott Laboratories Business Overview
  4. 7.1.3 Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  6. 7.1.5 Abbott Laboratories Recent Developments
  7. 7.2 Eli Lilly and Company
  8. 7.2.1 Eli Lilly and Company Company Information
  9. 7.2.2 Eli Lilly and Company Business Overview
  10. 7.2.3 Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  12. 7.2.5 Eli Lilly and Company Recent Developments
  13. 7.3 Hindustan Antibiotics
  14. 7.3.1 Hindustan Antibiotics Company Information
  15. 7.3.2 Hindustan Antibiotics Business Overview
  16. 7.3.3 Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  18. 7.3.5 Hindustan Antibiotics Recent Developments
  19. 7.4 Otsuka Pharmaceutical
  20. 7.4.1 Otsuka Pharmaceutical Company Information
  21. 7.4.2 Otsuka Pharmaceutical Business Overview
  22. 7.4.3 Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  24. 7.4.5 Otsuka Pharmaceutical Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 Mylan
  32. 7.6.1 Mylan Company Information
  33. 7.6.2 Mylan Business Overview
  34. 7.6.3 Mylan Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Mylan Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  36. 7.6.5 Mylan Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Novartis
  44. 7.8.1 Novartis Company Information
  45. 7.8.2 Novartis Business Overview
  46. 7.8.3 Novartis Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novartis Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  48. 7.8.5 Novartis Recent Developments
  49. 7.9 Sanofi
  50. 7.9.1 Sanofi Company Information
  51. 7.9.2 Sanofi Business Overview
  52. 7.9.3 Sanofi Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sanofi Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  54. 7.9.5 Sanofi Recent Developments
  55. 7.10 Teva Pharmaceutical
  56. 7.10.1 Teva Pharmaceutical Company Information
  57. 7.10.2 Teva Pharmaceutical Business Overview
  58. 7.10.3 Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
  60. 7.10.5 Teva Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue (2021-2032)
  2. 8.2 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2032)
  3. 8.2.1 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026)
  4. 8.2.2 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032)
  5. 8.3 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032)
  6. 8.4 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2032)
  7. 8.4.1 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026)
  8. 8.4.2 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032)
  9. 8.5 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032)
  10. 8.6 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country
  11. 8.6.1 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021-2026)
  13. 8.6.3 North America Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue (2021-2032)
  2. 9.2 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032)
  5. 9.3 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032)
  9. 9.5 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country
  11. 9.6.1 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Necrotizing Ulcerative Gingivitis (NUG) Revenue (2021-2032)
  2. 10.2 China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2032)
  3. 10.2.1 China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026)
  4. 10.2.2 China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032)
  5. 10.3 China Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032)
  6. 10.4 China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2032)
  7. 10.4.1 China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026)
  8. 10.4.2 China Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032)
  9. 10.5 China Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue (2021-2032)
  2. 11.2 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032)
  5. 11.3 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032)
  9. 11.5 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country
  11. 11.6.1 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue (2021-2032)
  2. 12.2 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country
  11. 12.6.1 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Necrotizing Ulcerative Gingivitis (NUG) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst